02 Oct TomoTherapy forecasts 61 percent Q3 revenue surge
Madison, Wis. – TomoTherapy has filed an amendment to its registration statement with the Securities and Exchange Commission that includes preliminary revenue estimates of between $58 million and $60 million for the third quarter of 2007, which would represent a 61 percent increase over the same quarter of 2006.
That projection compares to revenue of $37.2 million for the third quarter of 2006, and $43.7 million during the second quarter of 2007.
TomoTherapy manufactures the Hi-Art radiation therapy system to treat a variety of cancers. As of September 30, 2007, the Madison-based company had a worldwide installed base of over 150 units and estimates that its backlog was at least $225 million.
TomoTherapy will review its actual third quarter performance in an investor conference call on Tuesday, October 30. In May of this year, the company netted more than $180 million in an initial public offering of stock that is traded on the NASDAQ Global Market.
• TomoTherapy files to sell 8.5 million additional shares of stock
• Tom Still: High-end exports can distinguish Wisconsin in China’s emerging markets – for now
• TomoTherapy sells first radiation therapy system in China
• TomoTherapy founder says investors should take long view of company performance